In an attempt to expand its sleep disorder franchise, Jazz Pharmaceuticals has agreed to in-license Sumitomo Pharma’s Phase I orexin-2 receptor agonist, DSP-0187, for the potential treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. The deal, worth up to US$1.59 B, grants Jazz the exclusive license to develop and commercialise the drug in the US, Europe and other territories. The agreement represents Jazz’s third deal to license or divest an asset in the past five weeks, as the company strives to meet its ‘Vision 2025’.